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Purpose: To evaluate the influence of germ-cell tumour therapy on sexual functioning and subjective quality of life (QL). To
investigate the communication about sexual problems between patients, their partners, and doctors. In all, 474 patients treated for
germ-cell tumours at the Department of Internal Medicine III, Ludwig-Maximilians-University Munich, from 1979 to 2000 were asked
to complete a self-report questionnaire concerning psychosocial dimensions and subjective QL (QLS; Henrich and Herschbach,
2000). In total, 341 patients returned a completed questionnaire (response rate, 71.9%). The median age at survey was 41.9 years
and the median follow-up period after therapy was 9.6 years. Persisting sexual sequelae were lower than in the current literature:
decreased sexual desire (7.1%), erection (10.0%), orgasm (10.2%), ejaculation (28.8%), sexual activity (8.5%), and sexual satisfaction
(4.8%). In QL the satisfaction with ‘friends/acquaintances’ (Po0.001) and ‘family life/children’ (Po0.001), is lower than in the healthy
population. Correlations between functional scales and subjective QL were highly significant. There is a strong correlation between
sexual satisfaction and global life satisfaction (Spearman’s Rho: 0.48; Po0.01). A total of 61.4% of patients were not offered
communication about sexual problems by their doctors and 21.2% were unable to talk with their partner about sexual issues. In
conclusion, moderating psychosocial variables (e.g. personality factors, cognitive processes) should be investigated to clarify the
relationship between life satisfaction (subjective QL) and functional impairments. Communication about sexual problems should be
offered as a standard to patients treated for germ-cell tumours.
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Testicular cancer is the most frequent malignancy in young adult
males, aged 20–35 years. The incidence has increased significantly
over the last two decades (Che et al, 2002). Germ-cell tumours are
highly sensitive to cisplatinum-based chemotherapy, resulting in
cure rates of over 90% for patients with minimal metastatic
disease, and in 70–80% of patients with metastatic disease
(Bokemeyer et al, 1999; Schmoll, 1999; Gerl, 2000). Since most of
the patients are going to be long-term survivors with high life
expectancy, long-term sequelae (Strumberg et al, 2002), side effects
and secondary morbidities (Hartmann et al, 1999, 2000), as well as
psychosocial difficulties, sexual life problems and quality-of-life
(QL) issues have become the major long-term complications of
testicular cancer treatment. The diagnosis of germ-cell tumours
often falls in a life-phase, when young adult men are usually in the
prime of their physical health, starting their professional career,
and are planning to have a family.
Most studies focus on sexual dysfunction after germ-cell tumour
therapy (Bohlen et al, 2001; Jonker-Pool et al, 2001). Some describe
the influence on health-related QL (Fossa et al, 1999; Joly et al,
2002). Others show the necessarity of an open dialogue between
doctors and patients on sexual difficulties (Bourgeois-Law and
Lotocki, 1999; Hawighorst-Knapstein et al, 2002). Only few studies
ask for sexual satisfaction as an area of subjective QL. Subjective
QL reflects the difference between an individual’s hopes, expecta-
tions, and desires and what he or she considers as reality (Calman,
1984).
The WHO defines sexual health as ‘a state of physical,
emotional, mental and social well-being related to sexuality; it is
not merely the absence of disease, dysfunction or infirmity’.
According to this definition, sexual well-being is a complex
phenomenon, which comprises physical and psychosocial ele-
ments. It also illustrates the difference between sexual functioning
and sexual well-being.
There is a broad consensus that two elements are essential to
measure QL, namely, multidimensionality and subjectivity (Cella,
1998). Multidimensionality means that the definition must cover
different relevant aspects or dimensions of QL, at a minimum
physical, mental, and social aspects. Subjectivity reflects the
everyday experience that the specific factors determining the
quality of a person’s life are both highly personal and virtually
limitless. Moreover, there are great inter- and intraindividual
differences in the perception and evaluation of objective aspects of
life or disease.
Goals of investigation
The present study was designed to evaluate the influences of germ-
cell tumours and their therapy on psychosocial dimensions (sexual
functioning, social support, communication about sexual problems Received 20 August 2003; accepted 24 September 2003
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lwith partner and doctor) and subjective QL. A specific focus was
the relationship between functional parameters and areas of
subjective QL.
PATIENTS AND METHODS
Patients treated for testicular cancer at the department of internal
medicine III, Ludwig-Maximilians-University Munich, from 1979
to 2000 were asked to complete a self-report questionnaire
concerning psychosocial dimensions and subjective QL. The
following eligibility criteria were defined: (1) histologically proven
germ-cell tumour or extragonadal germ-cell tumour of the
retroperitoneum, (2) absence of progression or second malignancy
at survey time, (3) age at least 18 years, (4) absence of psychiatric
disease or mental disability.
Clinical staging had been performed according to the TNM
classification system. According to the treatment modality,
patients were divided into three subgroups: (1) men treated with
orchidectomy; (2) men treated with orchidectomy and chemother-
apy; and (3) men treated with orchidectomy, chemotherapy, and
retroperitoneal lymph node dissection (RLND).
Questionnaire
As no validated question was available for germ-cell tumour
patients in our study, we designed a questionnaire that contained
items on general health status, social support, relationship, body
image, communication with partner and doctors about sexual
problems, and fertility/sexual functioning. The questions in the
self-report inventory were of the rating type, mostly ordinal-scaled
with five ranks (‘not at all’, ‘slight’, ‘moderate’, ‘quite’, ‘very’).
The questionnaire contained three sections:
(1) Sociodemographic data
(2) ‘Questionnaire for germ-cell tumour patients in surveillance’
(33 items)
(3) ‘Questionnaire on partnership and sexual functioning’ (19
items)
Copies of the questionnaire are available from the authors on
request.
Additionally, the patients received the ‘Questions on Life
Satisfaction’ (QLS; Henrich and Herschbach, 2000), which is a
validated, short questionnaire for assessing subjective QL
(Figure 1). It covers eight areas of life satisfaction: ‘friends/
acquaintances’, ‘leisure time/hobbies’, ‘health’, ‘income/financial
security’, ‘occupation/work’, ‘housing/living conditions’, ‘family
life/children’, and ‘partner relationship/sexuality’. In the evalua-
tion of the responses, the ratings for importance and satisfaction
are combined to yield information about ‘weighted satisfaction’,
which varies between  12 and þ20. The weighting formula is:
wS¼importance ratingn((2nsatisfaction rating) 3), provided
both ratings are made on scales ranging from 0 to 4. The measure
of ‘Global Life Satisfaction’ is the sum of the wS values.
Patients
The questionnaire was sent to 474 patients in April 2000. To
include patients who had moved without leaving their new
residence address, the residents’ registration office was also
consulted. Every patient who fulfilled the eligibility criteria was
asked to participate. Prior to its initiation, the study was approved
by the Ethics Committee of Ludwig-Maximilians-University,
Munich.
Statistical analysis
To portray the clinical relevance of the results in interpretive
percentages, the raw scores for the five-point ranking-scales were
combined to three categories: ‘not at all/slight’, ‘moderate’, and
‘quite/very’.
The primary results of the study are descriptive, the secondary
results inferential. In bivariate analysis (Spearman’s correlation),
we determined associations between functional limitations and
areas of subjective QL. With the Kruskal–Wallis test, we analysed
differences for the treatment regimens and the groups after
therapy (0–6, 6–12, and over 12 years). t-Tests for independent
samples were used to investigate the differences between subjective
QL in germ-cell tumour patients and healthy Germans. Ordinal
regression analysis and MANOVA were used to control the
influence of age (at survey, at diagnosis) and time after treatment
as confusing parameters on psychosocial consequences and QL.
All P-values are Bonferroni corrected. Differences were con-
sidered to be statistically significant at Pp0.05. Statistical tests
were performed using the SPSS computer program, version 11.0.
RESULTS
Participation in the study
From the 474 patients asked to participate, 341 returned a
completed questionnaire, 22 refused participation, seven died,
and 104 moved untraceably (response rate, 71.9%).
Respondent characteristics
Table 1 provides an overview of the patients’ characteristics. At the
time of the study, the median age of the total patient group was
41.9 years (range 22–75 years). At the time of diagnosis, the
median age of the total patient group was 31.2 years (range 16–59
years; s.d.¼8.7 years). The median follow-up period was 9.6 years
after the diagnosis of germ-cell tumour (range 1–22; s.d.¼5.7
years). In all, 64 patients (19.0%) underwent orchidectomy and
surveillance, 83 patients (24.6%) additional chemotherapy (e.g.
PEB, PVB, ECBC), and 190 patients (56.4%) further RLND.
How important are the following areas for your quality of life?
1.  Friends/acquaintances 1  2   4  5 
2.  Leisure time/hobbies 1  2   4  5 
3.  Health 1  2   4  5 
4.  Income/financial security 1  2   4  5 
5.  Occupation/work 1  2   4  5 
6.  Housing/living conditions 1 2  4   5 
7.  Family life/children 1  2   4  5 
8.  Partner relationship 
/sexuality
1 2  4   5 
How satisfied are you with the following areas of quality of life?
Comp- 
letely
unsatis- 
fied
Slightly
unsatis-
fied
Totally
unsatis-
fied
Quite 
unsatis-
fied
Slightly
satis-
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1. 1 
2. 1 
3. 1 
4. 1 
5. 1 
6. 1 
7. 1 
8. 1 
3
3 
3
3 
3
3
3
3
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2   4  5 
2   4  5 
2   4  5 
2   4  5 
2 4  5 
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Figure 1 Questions of Life Satisfaction (QLS)
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lSexual functioning and psychosocial sequelae after germ-
cell tumour therapy
Table 2 provides information about the reported incidence of
post-treatment sequelae after germ-cell cancer therapy (general
health status, sexual attractivity, libido, arousal, erection, ejacula-
tion, and orgasm). The decrease in ejaculation depends on
therapy regimens (orchidectomy, plus chemotherapy, plus retro-
peritonal lymph node dissection; Kruskal–Wallis’ w
2: 28.7, df¼2;
Po0.001).
Table 3 presents information about subjective perceived
sequelae through germ-cell tumour therapy. In sexual activity
(Po0.001), sexual interest (Po0.001), as well as in sexual
satisfaction (Po0.001), there is a highly significant decrease in
the patients’ perception before and after therapy.
Asked for specific sexual problems before and after therapy, 75
patients (22.0%) reported ‘fear of sexually dissatisfying my
partner’ after therapy (before therapy: 30 patients, 9.6%; w
2: 45.6;
df¼1; Po0.001). 32 patients (9.6%) reported ‘inhibitions against
my partner’ after therapy (before therapy: eight patients, 2.5%; w
2:
40.8; df¼1; Po0.001).
The above sequelae occurred first, in 28 patients (14.4%)
‘immediately after diagnosis’, in 13 patients ‘at the beginning of
therapy’, in 27 cases (13.8%) ‘during therapy’, and in 127 cases
(65.1%) ‘after therapy’.
There was no significant influence of time between end of
therapy and survey point (0–6, 6–12, and over 12 years). Ordinal
regression analysis with stage and type of disease as factors, and
age (at survey, at diagnosis), as well as years since end of therapy
as covariates showed only one significant influence from ‘age at
survey’ (positive taxator; P¼0.001), ‘age at diagnosis’ (negative
taxator; P¼0.005), and ‘time since end of therapy’ (negative
taxator; P¼0.003) on ‘health status after therapy’. This demon-
strates that older patients at survey time, younger patients at
diagnosis, and patients treated recently for germ-cell tumours
report a more severe decrease of health status after therapy. There
were no indications in ordinal regression models that younger
patients at diagnosis were in advanced stages of their disease. No
significant influences were found for the dependent variables
‘sexual attractivity’, ‘sexual arousal’, ‘libido’, ‘quality of orgasm’, as
well as ‘sexual activity’, ‘sexual interest’, and ‘sexual satisfaction’.
A total of 117 patients (35.1%) had fathered children before
diagnosis (range 1–5; median¼2). 196 patients (58.9%) wished to
father children after treatment, and 104 patients were unable to do
so. In all, 26 patients (25.0%) reported severe distress, caused by
the unfulfilled wish for children, 28 (26.9%) reported moderate,
and 50 patients (48.1%) ‘no/slight’ distress.
Totally, 293 patients (85.9%) felt strongly socially supported
through their family in the process of coping with the disease, 16
patients (4.7%) received moderate, and 32 patients (9.4%) ‘no/
slight’ social support.
Communication about sexual problems
A total of 68 patients (21.2%) were ‘never/seldom’ able to talk with
their partner about sexual problems, whereas 188 patients (58.8%)
Table 1 Patients’ characteristics (n¼341)
Variable Frequency Percentage
Age (years)
20–30 38 11.1
30–40 137 40.2
40–50 102 29.9
50–60 44 12.9
60–70 17 5.0
70–80 3 0.9
Type of disease
Seminoma 75 22.0
Non-seminoma 266 78.0
Stadium of disease
1 94 27.6
2 144 42.2
3 103 30.2
Therapy
Orchidectomy 64 19.0
plus chemotherapy 83 24.6
plus RLND
a 190 56.4
Family status
Single 101 30.8
Partnered/married 203 61.9
Divorced/separated 24 7.3
Widowed 0 0.0
Partnership (year(s))
0–1 27 9.3
1–10 124 42.6
10–20 82 28.2
20–30 35 12.0
Over 30 23 7.9
Educational level
Elementary school 89 26.3
Secondary school 74 21.9
High school degree 67 19.8
University degree 108 32.0
Employment status
Full-time 263 79.2
Part-time 18 5.4
Unemployed 3 0.9
Houseman 2 0.6
In training 16 4.8
Retired 30 9.0
aRetroperitoneal lymph node dissection.
Table 2 Sequelae of germ-cell tumour therapy
Variable Moderate Quite/very
Decreased general health status 45 (13.2%) 34 (10.0%)
Decreased sexual attractivity 40 (11.8%) 41 (12.0%)
Libido loss 42 (12.4%) 24 (7.1%)
Arousal loss 44 (13.0%) 29 (8.6%)
Decreased erection 36 (10.7%) 34 (10.0%)
Decreased ejaculation 13 (3.9%) 97 (28.8%)
Decreased orgasm intensity 36 (10.7%) 34 (10.1%)
Table 3 Subjective perceived sequelae through germ-cell tumour therapy – n (%)
Before therapy After therapy
Variable No/slight Moderate Quite/very P No/slight Moderate Quite/very
Sexual activity 58 (17.6%) 87 (26.4%) 184 (56.0%) o0.001 89 (26.9%) 90 (27.2%) 152 (45.9%)
Sexual interest 11 (3.3%) 61 (18.3%) 262 (78.4%) o0.001 39 (11.7%) 58 (17.4%) 236 (70.9%)
Sexual satisfaction 45 (13.6%) 83 (25.2%) 202 (61.2%) o0.001 79 (24.0%) 86 (26.1%) 164 (49.9%)
Germ-cell tumour therapy
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tions). In all, 35 patients (10.5%) ‘often/always’ wished to have
more information on sexual problems from their doctors, 123
(36.9%) ‘sometimes’, and 175 (52.6%) ‘never/seldom’. Totally, 200
patients (61.4%) reported that their doctors did ‘not/seldom’ offer
communication about sexual problems, and 75 (23.0%) reported a
moderate offer (51 rated ‘often/always’). The wish for more
information on sexual problems from the doctors correlates
negatively with the quantity of communication between patients
and doctors (Spearman’s Rho:  0.20; Po0.001).
Subjective quality of life
The results of the QLS in comparison with the healthy German
population are listed in Table 4. There are highly significant
differences in the dimension ‘friends/acquaintances’ and ‘family
life/children’. Patients treated for malignant germ-cell tumours are
less satisfied with these areas.
A MANOVA showed no significant influences of the factors
‘stage’ and ‘type of disease’ and of the covariates ‘age’ (at survey, at
diagnosis) and ‘years since end of therapy’ on the areas of life
satisfaction.
Sequelae in ‘general health status’, ‘orgasm intensity’, ‘partner
communication on sexual problems’, ‘sexual activity’, and ‘sexual
satisfaction’ are correlated highly significantly with several areas of
life satisfaction. Table 5 illustrates highly significant correlations
with a Spearman’s Rho X0.30.
DISCUSSION
The present study demonstrates several correlations between
sexual functioning and subjective QL, assessed by the QLS. In
contrast to other QL measures, the QLS comprises levels and
weights of life satisfaction. Our data suggest that there are long-
lasting differences between the QL of germ-cell tumour patients
and healthy Germans. Patients seem to have less satisfactory social
contacts with their ‘friends/acquaintances’. This might come from
long-lasting social avoidance, or impeding inhibitions of patients
to talk openly about their disease (Flanagan and Holmes, 2000).
Interestingly, no significant correlations were found between the
collected data and this area.
The unfulfilled wish for children in 104 patients may explain the
lower values of satisfaction in ‘familiy life/children’, as 51.9%
reported moderate or severe distress. Childlessness is often a
major threat to QL in testicular cancer survivors (Rieker et al,
1990). The number of patients who had already fathered children
before diagnoses (35.1%) parallel the results from an earlier study
(Bohlen et al, 2001). Additionally, limited partner communication
about sexual problems is correlated with this area; 41.2% of
patients mentioned moderate-to-severe limitations in their partner
dialogue.
Although there were several limitations in sexual functioning,
the life satisfaction in ‘partner relationship/sexuality’ did not differ
significantly from the healthy German population. Most correla-
tions are weak, supposing other, modulating psychosocial
variables (e.g. personality, cognitive processes).
The prevalence rate of sexual dysfunction in this paper is lower
than that in the literature. Jonker-Pool et al (2001) reviewed
publications from 1975 to 1999 in a meta-analysis (36 studies with
a total of 2786 cases). In the present study, the patients reported
lower limitations in sexual desire (7.1 vs 19.6%), erection (10.0 vs
11.5%), orgasm (10.2 vs 19.8%), ejaculation (28.8 vs 44.2%), sexual
activity (8.5 vs 24.2%), and sexual satisfaction (4.8 vs 19.1%); they
are older (41.9 vs 34.7 years), and the follow-up is more extended
(9.6 vs 6.9 years). The recent study of Incrocci et al (2002) also
reports higher functional problems. Since most of the studies in
this research area used self-designed questionnaires, it is difficult
to compare their results. Standard instruments, containing
normative data, should be developed for investigation in sexual
sequelae of cancer patients.
The younger the patients at diagnosis, the shorter the time
between treatment and survey, and the older the patients at survey
time, the higher were the impairments in general health status.
Since the last factor covers the ageing process, and the medium
factor depends on persisting treatment side effects, the first factor
could describe worsening effects of cancer treatment on general
health status, especially in young adult males (Greenberg et al,
1997; Bauld et al, 1998).
Not surprisingly, the ejaculatory dysfunction depended on
treatment regimens.
The treatment of germ-cell tumours seems to have highly
significant influences on sexual activity, interest, and satisfaction.
Asked when sexual problems first occurred, 21.1% reported
‘immediately after diagnosis’ or at the ‘beginning of therapy’. This
indicates that sexual dysfunction in testicular cancer also implies
psychological factors (van Basten et al, 1997), besides somatic side
effects of therapy.
There are disillusioning results on the patient–doctor
communication about sexual problems. As 21.2% of patients
‘never/seldom’ were able to talk with their partner about
sexual problems, 61.4% reported that their doctor, treating for
germ-cell tumour, did ‘not/seldom’ offer communication about
sexual problems. This needs further investigation, to also
assess the doctors’ rating and eliminating possible recall biases.
In the total German population, only 11% of the patients were
Table 4 t-Test on Life Satisfaction on germ-cell tumour patients
(n¼324) and healthy German population (n¼2534, Henrich and
Herschbach, 2000)
Variable M s.d. P M s.d.
Friends/acquaintances 6.7 5.9 o0.001 8.1 6.3
Leisure time/hobbies 5.9 5.7 NS 6.3 6.3
Health 8.7 6.6 NS 8.1 7.5
Income/financial security 6.0 5.7 NS 6.5 7.3
Occupation/work 6.0 6.2 NS 5.5 7.3
Housing/living conditions 8.0 5.7 NS 8.3 6.4
Family life/children 8.2 8.2 o0.001 9.8 6.9
Partner relationship/sexuality 7.3 8.7 NS 7.9 7.7
Global Life Satisfaction 56.7 30.8 NS 60.5 37.3
Table 5 Correlation between sequelae of germ-cell tumour therapy and Life Satisfaction (Spearman’s Rho X0.30; Po0.01)
Areas of Life Satisfaction
Sequelae in y Health Occupation/work Family life/children Partner relationship/sexuality Global life satisfaction
General health status 0.42 0.30 NS NS 0.30
Orgasm intensity NS NS NS 0.30 0.32
Partner-communication on sexual problems NS NS 0.30 0.33 0.39
Sexual activity NS NS NS 0.35 NS
Sexual satisfaction 0.31 NS NS 0.62 0.48
Germ-cell tumour therapy
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(Hartmann et al, 2002).
In conclusion, the present study shows lower limitations in
sexual functioning than previously reported in the literature for
germ-cell tumour patients. There seem to be persisting impair-
ments in life satisfaction in ‘friends/acquaintances’ and ‘family life/
children’. The correlations between subjective QL and functioning
scales are highly significant. There is a strong correlation between
sexual satisfaction and global life satisfaction. Modulating
psychological variables (e.g. personality, cognitive processes)
should be investigated. Sexual problems should be discussed with
all patients before the start of treatment and at follow-up
examination (Kunkel et al, 2000).
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